News
MSD claims 2nd FDA approval for Welireg, in kidney cancer
The FDA has approved MSD’s oral HIF-2 alpha inhibitor Welireg for a second cancer indication, relapsed or refractory advanced renal cell carcinoma (RCC), the most common f
